VXLLF (Vaxil Bio) EPS without NRI: $0.13 (TTM As of Mar. 2026)


VXLLF Vaxil Bio Ltd VXLLF
38 GF Score
Price $0.04
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio EPS without NRI?

Vaxil Bio VXLLF 38 EPS without NRI is $0.13 as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 1,170 Biotechnology companies, Vaxil Bio ranks worse than 85470% on this metric.

Vaxil Bio's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Vaxil Bio's EPS without NRI or its related term are showing as below:

During the past 13 years, Vaxil Bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 58.80% per year. The lowest was 0.00% per year. And the median was 38.30% per year.

VXLLF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.75
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Vaxil Bio's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.13.

Vaxil Bio's EPS (Basic) for the three months ended in Mar. 2026 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.13.


Vaxil Bio  (OTCPK:VXLLF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vaxil Bio EPS without NRI Related Terms


Vaxil Bio EPS without NRI Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio EPS without NRI Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.39 -0.37 -0.08 -0.03 0.00

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.01 -0.01 0.15 -0.02

VXLLF vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Vaxil Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxil Bio PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's PE Ratio without NRI falls into.


VXLLF
38GF Score
Vaxil Bio Ltd VXLLF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.13 mean?
Vaxil Bio (VXLLF) has a EPS without NRI of $0.13 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Vaxil Bio and its competitors. According to the industry distribution chart, Vaxil Bio ranks #999999 out of 1170 companies in the Biotechnology industry.
Is Vaxil Bio's EPS without NRI too high?
Vaxil Bio's current EPS without NRI is $0.13. The Biotechnology industry median EPS without NRI is 16.75. Vaxil Bio's value of $0.13 is 99.2% below this industry median. Based on the distribution chart, Vaxil Bio ranks #999999 out of 1170 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #999999 out of 1170 companies for EPS without NRI. This places Vaxil Bio in the lower half of its industry. The industry median EPS without NRI is 16.75. Vaxil Bio's value of $0.13 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxil Bio's current EPS without NRI of $0.13 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Vaxil Bio and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxil Bio's current EPS without NRI is $0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current EPS without NRI of $0.13. The current EPS without NRI is $0.13 and 99.2% below the Biotechnology industry median of 16.75. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current EPS without NRI is $0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score

Get the complete analysis for VXLLF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price